Sacral nerve stimulation


Sep 2020

On September 03, 2020, the National Institute for Health and Care Excellence (NICE) issued medical technologies guidance on Axonics sacral neuromodulation (SNM) system for treating refractory overactive bladder. NICE recommended Axonics SNM to be adopted in the NHS and considered as an alternative when another treatment is not effective. Read more


Feb 2020

Axonics sacral neuromodulation would be an option for people with symptoms of the overactive bladder who have not responded to conservative treatments or drug therapy. The Axonics could save the NHS around £6,200 per patient if the device lasts more than six years. Consultations are open to the stakeholders until March 13, 2020. Read more


Apr 2019

The report presents a summary of reimbursement situation for sacral nerve stimulation. The following indications will be considered: urge urinary incontinence, retention of urine, faecal incontinence. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. Read more


Feb 2019

In December 2018, the National Institute for Health and Care Excellence (NICE) published one new diagnostic guidance (for tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer), two new interventional procedure guidance (for transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults and bronchial thermoplasty for severe asthma), and four MedTech innovation briefings. Read more